Piper Jaffray Companies cut shares of Audentes Therapeutics (NASDAQ:BOLD) from an overweight rating to a neutral rating in a research note released on Tuesday, Benzinga reports. They currently have $60.00 price objective on the biotechnology company’s stock, up from their previous price objective of $55.00.
A number of other research firms have also weighed in on BOLD. Zacks Investment Research lowered shares of Audentes Therapeutics from a buy rating to a hold rating in a report on Friday, November 8th. HC Wainwright reiterated a buy rating and set a $48.00 price target on shares of Audentes Therapeutics in a research note on Friday, November 8th. William Blair reissued a hold rating on shares of Audentes Therapeutics in a report on Wednesday, August 7th. Robert W. Baird raised Audentes Therapeutics from an underperform rating to a neutral rating in a research note on Tuesday. Finally, Evercore ISI upgraded Audentes Therapeutics from an in-line rating to an outperform rating in a report on Wednesday, November 27th. One equities research analyst has rated the stock with a sell rating, sixteen have given a hold rating and three have issued a buy rating to the company’s stock. The stock has a consensus rating of Hold and a consensus target price of $46.29.
BOLD traded up $0.05 during trading on Tuesday, hitting $59.26. 965,511 shares of the company’s stock were exchanged, compared to its average volume of 632,707. Audentes Therapeutics has a fifty-two week low of $17.95 and a fifty-two week high of $59.48. The stock has a market cap of $2.71 billion, a P/E ratio of -17.43 and a beta of 1.77. The business’s 50 day moving average is $29.57 and its two-hundred day moving average is $33.41.
In other Audentes Therapeutics news, Director Louis G. Lange sold 10,000 shares of Audentes Therapeutics stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $32.16, for a total transaction of $321,600.00. Following the transaction, the director now owns 276,044 shares of the company’s stock, valued at approximately $8,877,575.04. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Matthew R. Patterson sold 14,426 shares of the business’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $30.00, for a total value of $432,780.00. Following the completion of the transaction, the chief executive officer now owns 127,820 shares in the company, valued at approximately $3,834,600. The disclosure for this sale can be found here. 5.30% of the stock is currently owned by insiders.
Several hedge funds have recently added to or reduced their stakes in BOLD. Dupont Capital Management Corp purchased a new stake in shares of Audentes Therapeutics during the second quarter valued at approximately $745,000. Prudential Financial Inc. lifted its holdings in Audentes Therapeutics by 272.3% during the second quarter. Prudential Financial Inc. now owns 78,218 shares of the biotechnology company’s stock worth $2,961,000 after acquiring an additional 57,210 shares during the period. Point72 Asset Management L.P. lifted its holdings in Audentes Therapeutics by 7.8% during the third quarter. Point72 Asset Management L.P. now owns 241,100 shares of the biotechnology company’s stock worth $6,772,000 after acquiring an additional 17,483 shares during the period. Altshuler Shaham Ltd purchased a new position in Audentes Therapeutics in the second quarter worth $669,000. Finally, Voloridge Investment Management LLC purchased a new position in Audentes Therapeutics in the second quarter worth $993,000. 98.08% of the stock is owned by institutional investors.
Audentes Therapeutics Company Profile
Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.
Read More: What is the return on assets (ROA) ratio?
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.